Sections 201, 502, 505, and 701 of the
Federal Food, Drug, and Cosmetic Act require that marketed drugs be
safe and effective. In order to know whether drugs that are not
safe and effective are on the market, FDA must be promptly informed
of adverse experiences occasioned by the use of marketed drugs. In
order to help ensure this, FDA issued regulations at 21 CFR 310.305
and 314.80 to impose reporting and recordkeeping requirements on
the drug industry that would enable FDA to take action necessary
for protection of the public health from adverse drug
experiences.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.